|
|
|
Bio-IT World | Genentech and Complete Genomics have published the first full genome sequence of a primary lung tumor from a heavy smoker, leading to the calculation that one DNA mutation is triggered for every three cigarettes smoked.
|
Bio-IT World | Two years ago, walking around the exhibit hall at Bio-IT World Expo, an occasional contributor to this publication came up to me and said, “It feels like this event is finally coming of age.” If I didn’t entirely believe him then, I do now.
|
An Icelandic volcano didn't slow down the biggest Expo yet. By Kevin Davies May 18, 2010 | First Base | Two years ago, walking around the exhibit hall at Bio IT World Expo, an occasional contributor to this
|
The computational drug discovery company IDs ‘Lipinski enhanced’ compounds. By Kevin Davies May 18, 2010 | The British computational drug discovery company Domainex has announced it is participating in a new lead optimization collaboration with the Institute of Cancer Research
|
Expert Comment Myriad’s loss means gene patents advance to next level. By W. Edward Ramage and Claire Cowart Haltom May 18, 2010 | On Monday, March 29, 2010, the United States District Court for the Southern District of New York
|
Bio-IT World | The British computational drug discovery company Domainex is participating in a new Wellcome Trust-funded lead optimization collaboration with Alan Ashworth's team at the Institute of Cancer Research (ICR) in the search for new drugs for breast cancer. The partnership showcases the potential value of Domainex's rational approach to predicting optimal drug candidates.
|
Expert Commentary | On Monday, March 29, 2010, the United States District Court for the Southern District of New York delivered a serious blow to human gene patent holders. The opinion, the first round in the closely followed ACLU v. Myriad Genetics case, invalidates several patents with claims covering genes associated with breast cancer. The result surprised many in the biotechnology industry because the broad holding, if upheld on appeal, would eliminate future gene patenting as well as effectively make existing gene patents invalid.
|
March 16, 2010 | There isn’t an issue of Bio•IT World that doesn’t address the subject of personalized medicine in some respect. Many of our stories tackle issues of making medicine more predictive, more preventive, and more participatory—the concept encapsulated in “P4 medicine” by Lee Hood and colleagues (see “ISB Is a Sure Cure for Summer Doldrums,” Bio•IT World, July 2007). In recent years, the first examples of personalized diagnostics and therapies have emerged, with Herceptin leading the way. Biomarkers, gene expression profiles and next-generation sequencing approaches are dramatically changing the stratification and management of cancer. And the arrival of consumer genomics two years ago has empowered patients as never before.
|
Bio-IT World Weekly Update: Feb 23
|
Bio-IT World Weekly Update: Feb 16
|
Forbes | Daniel Vasella surprisingly announced he is stepping down as Novartis CEO. He will be succeeded by the head of pharmaceuticals, Joseph Jimenez, while remaining as chairman of the Swiss pharma.
|
January 20, 2010 | Inside the Box | Over the 2009 holiday shopping season, Amazon.com processed an estimated 73 items per second and 6.3 million items on a typical day. That may not come as much of a surprise. But what you may not know is that it’s all powered by cloud computing from Amazon Web Services (AWS). And Amazon isn’t even the biggest AWS customer, according to CEO Werner Vogels. Amazon’s Infrastructure as a Service is so far ahead in the cloud that competitors are struggling to keep pace. AWS is not about to rest on its laurels. Fortunately for the rapidly growing number of AWS users, it is aggressively innovating and improving its services. One might even say that during the 2009 holiday season, it left us some presents under the tree.
|
Bio-IT World | As we embark on a new year and a new decade, there’s not much doubt what biotech and pharma companies are wishing for: the ability to more accurately and expeditiously develop safe new drugs, ideally tailored (through companion diagnostics or patient stratification) to responsive segments of the population. In this issue of Bio•IT World, we present a collection of reports and interviews that showcase a variety of projects, people, and approaches that might bear fruit.
|
Bio-IT World | Andrew Kaczorek, associate information consultant with Eli Lilly, has been experimenting with Amazon Web Services (AWS). “The amount of time it spends and the amount of dollars it costs are entirely predictable. If [researchers] know exactly what workload that they’re pushing into it, they can know exactly when it should be done and how much their bill is going to be.”
|
Bio-IT World | SHENZHEN, CHINA—Boxing Day 2008: The Luohu border between Hong Kong and mainland China is crowded, smoky, and noisy. With my visitor’s visa to Shenzhen in hand, I’m cleared to visit the Beijing Genomics Institute’s (BGI’s) Shenzhen-based sequencing facility.
|
November 10, 2009 | Giles Day, senior director of informatics at Pfizer’s Biotherapeutics & Bioinnovation Center (BBC), has been experimenting with Amazon Web Services (AWS). “It really has transformed the way we do a lot of our work,” he said last April at the Bio-IT World Expo High Performance Computing & Storage workshop. “The pay-as-you-go model for us is really very, very nice.”
The line was echoed by Andrew Kaczorek, associate information consultant with Eli Lilly. “The amount of time it spends and the amount of dollars it costs are entirely predictable. If [researchers] know exactly what workload that they’re pushing into it, they can know exactly when it should be done and how much their bill is going to be.”
|
November 10, 2009 | SHENZHEN, CHINA—Boxing Day 2008: The Luohu border between Hong Kong and mainland China is crowded, smoky, and noisy. With my visitor’s visa to Shenzhen in hand, I’m cleared to visit the Beijing Genomics Institute’s (BGI’s) Shenzhen-based sequencing facility. Accompanied by my father and brother-in-law, I wave down the nearest cab. The cab driver doesn’t have the faintest idea where BGI is located. As none of us can handle his thick Mandarin accent, I’m forced to call Zhuo Li, vice president of BGI’s health care division. I hand the phone to the driver, and happily we’re deposited at BGI’s main entrance. It’s a tall gray-and-glass structure, distinctly newer and shinier than the neighboring buildings. My companions head across the street for a late breakfast (frog legs), and I wander in to meet Li.
|
Bio-IT World | British Columbia Cancer Agency's Marco Marra presented unpublished transcriptome sequencing studies at ASHG on two related genes mutated n Diffuse Large B-Cell Lymphoma.
|
Beckman Eyes Genomics Services Gold Rush
|
MediaGroup.com | Archives | Advertising | CHI Conferences | Subscribe
|
The Role of Analytics in Transforming Healthcare Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders. Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge.
BPM-Based Case Management Approach to Optimizing Clinical Trial Efficiency Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are: - Potentially stunning return on investment at multiple levels.
- A 500%, or better, increase in application development time by directly executing business requirements
- Improved customer retention
- A 50% possible reduction in training time
Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper.
Next-gen Cloud-based eClinical New technologies are available to leverage Cloud Computing in managing clinical trial data. This paper discusses a next generation eClinical
platform that: - Speeds trial set up
- Accommodates changes with zero downtime
- Integrates effectively with other clinical trial technology systems
It is offered with either software-as-a-service (SaaS), or turnkey infrastructure options in which the user organization operates their own cloud using their IT teams, within their data centers. Read this paper to learn and decide how best to leverage cloud computing’s many strengths for your organization’s particular needs.
Software Engineer – Computational Biology Center
Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.
Apply: www.mskcciscareers.org. Equal opportunity and affirmative action employer.
Bio-IT World proudly presents the Bio-IT World Web Symposia Series covering a broad array of topics within the life sciences and drug development enterprise.
Leveraging BPM to Increase Efficiencies in Clinical Trial Case Management
August 3, 2010 | 1:00 – 2:30 p.m. EST
Sponsored by: Pegasystems
Program Details | Register Here
|
|
|